Dublin, May 10, 2018 (GLOBE NEWSWIRE) -- The "Global Immunology Drugs Market to 2023 - Shifting Landscape as Uptake of Interleukin Receptor Inhibitors Offsets Losses for Top Blockbuster Drugs" report has been added to ResearchAndMarkets.com's offering.

Immunology drugs market is projected to grow to $113 billion in 2023, at a compound annual growth rate (CAGR) of over 8%

The market size in the US is expected to increase at a CAGR of 6.58%, therefore accounting for approximately half of the global immunology market.

The prevalence populations of many indications within immunology are increasing, which is one of the major drivers of the expected market growth. For example, the prevalence population of RA across the seven major markets is expected to increase from 6.11 million in 2016 to 6.66 million in 2023.

Immunology market contains a number of blockbuster drugs, most of which are mAbs that target tumor necrosis alpha (TNF-a), a key pro-inflammatory cytokine. These include Humira (adalimumab), the most successful drug industry-wide, as well as Remicade (infliximab), Rituxan (rituximab), Simponi (golimumab) and Cimzia (certolizumab pegol). However, due to several recent and upcoming patent expiries, this drug class will suffer from biosimilar erosion over the forecast period, resulting in revenue decline and reduced dominance.

The first TNF biosimilars were approved several years ago when the first patents expired, but they are only now starting to have an impact on the revenue of their premium counterparts. For example, Remsima and Inflectra are Remicade biosimilars that have been approved in the EU, and Inflectra also has FDA approval to be marketed in 2018 when the patent for Remicade expires in the US. These biosimilars are exerting a very noticeable impact on Remicade's revenue, which peaked in 2014 at $9.9 billion but is expected to fall to $3 billion by 2023.

Furthermore, there are also several drugs that have recently been approved - such as Cosentyx and Otezla - and several in late-stage pipeline development - such as, filgotinib, AR-101 and upadacitinib tartrate - that are expected to become blockbuster drugs over the forecast period, generating further market growth within immunology.

Key Topics Covered:

1 Tables & Figures

2 Introduction

• Therapy Area Overview
• Symptoms
• Diagnosis
• Etiology and Pathophysiology
• Epidemiology
• Co-morbidities and Complications

3 Key Marketed Products

• Humira (adalimumab) - AbbVie
• Enbrel (etanercept) - Amgen
• Remicade (infliximab) - Johnson & Johnson
• Rituxan (rituximab) - Roche
• Stelara (ustekinumab) - Johnson & Johnson
• Simponi (golimumab) - Johnson & Johnson
• Orencia (abatacept) - Bristol-Myers Squibb
• Tysabri (natalizumab) - Biogen
• Actemra (tocilizumab) - Roche
• Prograf (tacrolimus) - Astellas
• Cimzia (certolizumab) - UCB
• Entyvio (vedolizumab) - Takeda
• Cosentyx (secukinumab) - Novartis
• Otezla (apremilast) - Celgene
• Xeljanz (tofacitinib) - Pfizer
• Taltz (ixekizumab) - Eli Lilly

4 Pipeline Landscape Assessment

• Overview
• Pipeline Development Landscape
• Molecular Targets in the Pipeline
• Clinical Trials Landscape
• Clinical Trial Failure Rates
• Clinical Trial Duration
• Clinical Trial Size
• Cumulative Clinical Program Size
• Assessment of Key Late-Stage Pipeline Products
• Filgotinib - Galapagos and Gilead Sciences
• AR-101 - Aimmune Therapeutics
• Upadacitinib tartrate - AbbVie
• Lanadelumab - Shire
• Ozanimod hydrochloride - Celgene
• Risankizumab - AbbVie
• Conclusion

5 Multi-scenario Market Forecast to 2023

• Overall Market Size
• Generic Penetration
• Revenue Forecast by Molecular Target
• Cytokines and Cytokine Receptors
• Intracellular Signal Transducers
• Cell Surface Antigens
• Intercellular Interaction and Adhesion Molecules

6 Company Analysis and Positioning

• Revenue and Market Share Analysis by Company
• Company Landscape
• Marketed and Pipeline Portfolio Analysis

7 Strategic Consolidations

• Licensing Deals
• Co-development Deals

8 Appendix

Companies Mentioned

• AbbVie
• Johnson & Johnson
• Novartis
• Pfizer
• Roche
• Amgen
• Celgene
• Eli Lilly

For more information about this report visit https://www.researchandmarkets.com/research/sxn2hr/global_immunology?w=12

CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Immune Disorders Drugs